NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class (Ascending) | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
70771-1058-02 | 70771-1058 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb. 9, 2017 | In Use | |
70771-1058-03 | 70771-1058 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb. 9, 2017 | In Use | |
70771-1058-05 | 70771-1058 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb. 9, 2017 | In Use | |
70771-1058-07 | 70771-1058 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb. 9, 2017 | In Use | |
70771-1058-09 | 70771-1058 | Methotrexate | Methotrexate | 2.5 mg/1 | Chemotherapy | Antimetabolite | Folic Acid Analog | Oral | Feb. 9, 2017 | In Use | |
00781-3253-94 | 00781-3253 | Azacitidine | Azacitidine | 100.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Sept. 16, 2013 | Feb. 28, 2025 | In Use |
16729-0131-30 | 16729-0131 | FLUDARABINE | FLUDARABINE PHOSPHATE | 25.0 mg/mL | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Nov. 22, 2022 | In Use | |
55150-0393-01 | 55150-0393 | AZACITIDINE | AZACITIDINE | 100.0 mg/4mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, Subcutaneous | Jan. 3, 2023 | In Use | |
61703-0124-40 | 61703-0124 | Methotrexate | Methotrexate | 25.0 mg/mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intramuscular, Intrathecal, Intravenous, Subcutaneous | Jan. 9, 2023 | In Use | |
71288-0145-10 | 71288-0145 | Pemetrexed disodium | Pemetrexed | 100.0 mg/4.2mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | Dec. 13, 2022 | In Use |
Found 10,000 results in 5 milliseconds — Export these results